Aikido pharma notes advancement in radiopharmaceutical research

New york, april 16, 2021 /prnewswire/ -- aikido pharma inc. (nasdaq: aiki) ("aikido" or the "company") today noted that a recent study announced positive early results from a psma 617-lu177 study conducted by a leading global pharmaceutical company.  the report provides strong indications for analogous success in similar technology the company is helping to develop.
DOMH Ratings Summary
DOMH Quant Ranking